Drug Search Results
More Filters [+]

Labetalol

Alternative Names: labetalol, normodyne, trandate, normozide, trandate hct
Latest Update: 2024-12-17
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: ADRA1A Antagonist,ADRB Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous,Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Argentina | Australia | Austria | Bangladesh | Belgium | Canada | Chile | Colombia | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Iceland | India | Ireland | Israel | Italy | Jordan | Korea | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Portugal | Saudi Arabia | Singapore | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Turkey | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela

Approved Indications: None

Known Adverse Events: None

Company: Huabo Kaisheng Biotechnology
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Labetalol

Countries in Clinic:

Active Clinical Trial Count: 1

Highest Development Phases

Phase 3: Hypertension|Pregnancy Outcomes

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

PLATINA

P3

Active, not recruiting

Pregnancy Outcomes|Hypertension

2021-03-26

Recent News Events